Advanced search
Start date



Introduction: Vulvar cancer is a rare disease and accounts for 3-5% of all gynecological malignancies. The prognosis is related to lymph node involvement and stage. Surgery is the treatment cornerstone and includes primary tumor resection and inguinofemoral lymphadenectomy. Despite on clinical and pathological prognostic factors already described, some molecular markers are scarce. The identification of molecular marker may contribute to better understand the disease and development of new treatment strategies. In this scenario, studies regarding family ERBB are scarce.Objectives: 1- Evaluate immunohistochemical expression of ERBB family receptors in vulvar squamous cell carcinoma; 2- Evaluate ERBB family expression as a prognostic factor; 3- Correlate ERBB family expression with clinical and pathological variables.Methods: The retrospective analysis will include 234 patients with vulvar cancer treated in Department of Gynecologic Oncology from January 1980 to February 2010. Of these, 107 patients had inguinal lymph node metastasis. Clinical and pathological characteristics will be analyzed and ERBB expression will be evaluated in primary tumor and lymph node metastasis.Expected results: The identification of molecular markers in vulvar cancer (primary tumor and metastatic lymph node) may contribute to better understand the disease biology and further development of new treatment strategies with target drugs. (AU)